Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
OBJECTIVE
Pancreatic cancer (PC) is a malignant tumor with high mortality. Aggressive growth and metastases of PC are the result of basement membrane degradation that may be attributed to the action of matrix metalloproteinase-9 (MMP-9). The aim of the study was to determine the diagnostic and prognostic significance of the measurements of serum MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with PC.


METHODS
The study involved 78 patients with PC, 45 with chronic pancreatitis, and 70 healthy subjects. We assayed the serum concentrations of MMP-9, TIMP-1, and classic tumor markers (carbohydrate antigen 19-9 and carcinoembryonic antigen) and defined the prognostic value and the diagnostic criteria for all the proteins tested.


RESULTS
In the patients with PC, the serum levels of MMP-9, TIMP-1, and the tumor markers were higher as compared with those in the patients with chronic pancreatitis and the healthy subjects. The diagnostic sensitivity and the area under the receiver operating characteristic curve for TIMP-1 were higher than for MMP-9 and the tumor markers. The elevated preoperative concentration of MMP-9 was a significant independent prognostic factor for the patients' survival.


CONCLUSIONS
These findings indicate a potential clinical significance of serum TIMP-1 and MMP-9 measurements in the diagnosis and prognosis of patients with PC, respectively.
Mroczko
Barbara
B
Department of Biochemical Diagnostics, Medical University, Bialystok, Poland. mroczko@umwb.edu.pl
Lukaszewicz-Zajac
Marta
M
Wereszczynska-Siemiatkowska
Urszula
U
Groblewska
Magdalena
M
Gryko
Mariusz
M
Kedra
Boguslaw
B
Jurkowska
Grazyna
G
Szmitkowski
Maciej
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000201:enzymology* / Q000473:pathology; D050500:Pancreatitis, Chronic / Q000097:blood / Q000201:enzymology; D011379:Prognosis; D016019:Survival Analysis; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D019715:Tissue Inhibitor of Metalloproteinase-1; D020780:Matrix Metalloproteinase 9